|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Global_Gene_Therapy_Manufacturing_Facility
gptkb:Myonexus_Therapeutics
Lacerta Therapeutics (partial stake)
|
|
gptkbp:CEO
|
gptkb:Douglas_S._Ingram
|
|
gptkbp:collaboratesWith
|
gptkb:Duke_University
gptkb:Roche
gptkb:Nationwide_Children's_Hospital
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:focusesOn
|
rare diseases
genetic medicine
RNA-targeted therapeutics
|
|
gptkbp:founded
|
1980
|
|
gptkbp:founder
|
gptkb:James_E._Summerton
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sarepta Therapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:listedOn
|
gptkb:NASDAQ_Biotechnology_Index
gptkb:S&P_400
|
|
gptkbp:marketCap
|
multi-billion USD
|
|
gptkbp:milestone
|
first FDA-approved therapy for Duchenne muscular dystrophy
|
|
gptkbp:notableProduct
|
gptkb:Amondys_45
gptkb:Elevidys
gptkb:Exondys_51
gptkb:Vyondys_53
|
|
gptkbp:numberOfEmployees
|
2023
over 900
|
|
gptkbp:parentCompany
|
independent
|
|
gptkbp:patent
|
gene editing
RNA-based therapeutics
|
|
gptkbp:previousName
|
gptkb:AVI_BioPharma
gptkb:AntiVirals_Inc.
|
|
gptkbp:publiclyTraded
|
true
|
|
gptkbp:regulates
|
gptkb:FDA
|
|
gptkbp:researchArea
|
RNA splicing
antisense oligonucleotides
|
|
gptkbp:specializesIn
|
gptkb:Duchenne_muscular_dystrophy
gene therapy
precision genetic medicine
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:NASDAQ
gptkb:SRPT
|
|
gptkbp:therapeuticArea
|
neuromuscular diseases
rare pediatric diseases
|
|
gptkbp:website
|
https://www.sarepta.com/
|
|
gptkbp:bfsParent
|
gptkb:Dyno_Therapeutics
|
|
gptkbp:bfsLayer
|
6
|